GT20029
An experimental topical gel that degrades the androgen receptor in scalp cells. It has Phase 2 results but is not approved.
GT20029 Biological Classification
Investigated within physiological and chemical models.
What kind of compound
Small molecule
Investigational topical androgen-receptor degrader (PROTAC), developed by Kintor Pharmaceutical.
Human testing on file
1human record
0 animal · 1 total indexed. Phase 2 trials registered or reported.
Regulatory position
Investigational. One published Phase 2 trial; no approved product.
Studied for
Topical androgen-receptor degradation
Reviewed 13 November 2026
Known safety concerns in this file
- Phase 2 adverse events were mostly mild and similar across groups, according to the published report.
- Long-term effects of sustained androgen-receptor degradation in skin are unknown.
- No public chemical identity standard was identified, which limits independent quality assessment.
Commonly compared with
- Pyrilutamide — Blocks the androgen receptor rather than degrading it.
- Finasteride — Lowers DHT production systemically.
- RU58841 — Unapproved topical AR antagonist with unpublished trials.
What is GT20029?
An experimental topical gel that degrades the androgen receptor in scalp cells. It has Phase 2 results but is not approved. An investigational topical androgen-receptor degrader for androgenetic alopecia. A 180-participant Phase 2 trial in Chinese men was published in 2025; no approved product or public chemical identity standard exists.
Why are people interested in it?
Instead of blocking the androgen receptor, it aims to remove it. That is a different pharmacological bet from finasteride or pyrilutamide, and it is being tested directly in men with pattern hair loss.
Primary Research Categories
- Hair-follicle research
- Investigational drug substances
How does it work in the body?
A topical PROTAC-type molecule intended to mark androgen receptors for degradation, reducing androgen signalling in the follicle. The published Phase 2 trial tests the clinical consequence of that mechanism.
Biological Pathway Overview
GT20029 Receptor & Target Interactions
This compound is evaluated in scientific research for its interactions with target cellular receptors and signaling cascades. Consult the evidence section below for specific peer-reviewed papers.
Androgen receptor
Named in the published mechanism discussion for this compound.
Ubiquitin-proteasome degradation
Named in the published mechanism discussion for this compound.
DHT signalling
Named in the published mechanism discussion for this compound.
Key Distinction: An investigational or unapproved compound has no approved indication, and a proposed mechanism is not a demonstrated clinical effect.
What has actually been demonstrated in humans?
A randomised, placebo-controlled Phase 2 trial in 180 Chinese men with androgenetic alopecia was published in 2025. No Phase 3 trial or approval exists.
Pharmaceutical Reality vs. Unregulated Research Chemicals
Investigational. One published Phase 2 trial; no approved product. Phase 3 confirmation in a broader population.
What is still uncertain or unknown?
Phase 3 confirmation in a broader population. Durability after treatment stops. Long-term safety of local androgen-receptor degradation. A public identity standard for the drug substance.
Research at a Glance
Open the full evidence file (1 records)1 record in this file
- CLINICAL TRIAL1
Publication span: 2025
What Has Actually Been Studied
- Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a phase 2 study (Journal of Dermatological Treatment, 2025) — Phase 2 multicentre, randomised, double-blind, placebo-controlled trial.
What is Still Unknown
What we know
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
Preparation and Handling
Lyophilized peptides ship as freeze-dried powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific.
United States Regulatory Status
Investigational
- No approved product in Drugs@FDA as of this review.
- Phase 2 trial NCT06692465 randomised 180 Chinese adult men with androgenetic alopecia for 12 weeks and is registered as completed.
- The Phase 2 report describes significant improvements in target-area hair count in some dose groups versus placebo, with adverse events mostly mild and similar across groups.
- No public CAS number, molecular formula or pharmacopoeial identity standard was identified for GT20029. That is a documentation gap, not evidence about the molecule's activity.
- Androgen-receptor degradation is the proposed mechanism; Phase 3 confirmation and long-term safety are not available.
Technical Chemical SpecificationsClick to view CAS, sequence, and molecular formulas
- Molecular weight
- Unknown
- Sequence length
- Not recorded
- CAS number
- Unknown
- PubChem CID
- None assigned
- Compound class
- Investigational topical androgen-receptor degrader (PROTAC), developed by Kintor Pharmaceutical
- Sequence
- Unknown / Unassigned
- Molecular formula
- Unknown
- Molecular weight
- Unknown
- CAS number
- Unknown
- PubChem CID
- Unknown
Sources
Last reviewed 13 November 2026 · Compiled by Therapept Editorial · How these records are built